Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread

About this update from Arrowhead Pharmaceuticals, Inc.

[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced precautionary measures the company is taking to help protect the health and safety of its employees, partners, and the healthcare workers and patients involved in ongoing clinical studies of Arrowhead’s investigational medicines. Arrowhead does not expect these precautionary measures to materially affect the projected timelines for its development programs.\n\n\nCorporate Policy\n\n\nArrowhead is taking the following actions aimed at limiting the spread of COVID-19:\n\n\n\nProviding employees with flexibility around work schedules and recommending that they work from home, to the extent feasible and appropriate;\n\n\nRestricting all but the most essential business-related travel;\n\n\nImplementing a temporary easing of paid time off policies for any employee and/or family member illnesses and requiring ill employees to remain home for an extended time after symptoms subside;\n\n\nRestricting non-employee access to Arrowhead facilities; and\n\n\nEnhanced facility hygiene practices including increasing the frequency with which high touch surfaces are cleaned\n\n\n\nChris Anzalone, Ph.D., president and chief executive officer of Arrowhead, said: “The health and safety of Arrowhead employees and their families, the healthcare professionals involved in our clinical studies, and the patients who are participating in our clinical studies are of paramount importance to us. The current COVID-19 global health pandemic has led us to evaluate how our employees interact with each other and our vendors, and assess the impact of enrolling new patients in our ARO-AAT clinical studies, who, in some cases, travel across international borders to participate. We are committed to improving public health, and during extraordinary times like these we need to take appropriate actions that may help flatten the infection curve and reduce risk in vulnerable populations.”\n\n\nClinical Trials\n\n\nFor clinical trials of Arrowhead’s investigational medicines, the company is monitoring each program individually to determine if changes or accommodations are necessary. The COVID-19 pandemic is rapidly evolving, so Arrowhead will continue to assess the impacts, if any. The current status of each wholly-owned clinical program is as follows:\n\n\nARO-AAT for the Tr...

More updates from Arrowhead Pharmaceuticals, Inc.